PEP-0017Investigational

CARDIOGEN

Also known as

Short cardiac peptide studied for cardioprotection and tissue recovery. Preliminary evidence — investigational stage; published evidence is limited to preclinical models.

Evidence

Preliminary· 2.4

Animal or in-vitro only

Risk band

Elevated

Serious AEs reported or theoretical

Research goals

Tissue recovery

Summary

The literature retrieved under this name does not describe an administered therapeutic peptide. Instead it covers cardiac amyloidosis and transthyretin amyloid cardiomyopathy (ATTR-CM), including consensus statements that explicitly note a lack of randomized clinical trials and reliance on expert opinion and retrospective data [1,3,4], with "Cardiogen" appearing as the name of a French reference network for cardiac amyloidosis [4]. A separate item refers to CardioGen-82, a strontium-82/rubidium-82 generator used for cardiac PET imaging rather than a peptide drug [2]. No interventional trials of administering a "Cardiogen" peptide therapeutic are present, so no human therapeutic-efficacy claim can be supported from these sources.

Sources

  1. 1. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Global heart, 2023.
  2. 2. Update on CardioGen-82 Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012.
  3. 3. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association European heart journal, 2026.
  4. 4. [Cardiac amyloidosis] Annales de pathologie, 2021.

For educational purposes only.

← Back to the encyclopedia